msa-pathophysiology-disease-mechanisms

msa-pathophysiology-disease-mechanisms

--- [^1]
title: MSA Pathophysiology and Disease Mechanisms [^2]
description: Comprehensive mechanism page for Multiple System Atrophy pathophysiology, covering oligodendrocyte dysfunction, alpha-synuclein aggregation, and network degeneration. [^3] PMID: 24338664
published: true [^4]
tags: kind:mechanism, section:mechanisms, state:published [^5] PMID: 40719373
editor: markdown [^6]
pageId: 0 [^7]
dateCreated: "2026-03-26T07:35:00.000Z" [^8]
dateUpdated: "2026-03-26T07:35:00.000Z" [^9]
refs: [^10]
jellinger2023: [^11]
authors: Jellinger et al. [^12]
title: "Pathogenesis of multiple system atrophy (2023)" [^13] PMID: 30444295
journal: "Acta Neuropathol" [^14]
year: 2023 [^15]
doi: 10.1007/s00401-023-02567-4 [^16]
wenning2009: [^17]
authors: Wenning et al. [^18]
title: "Multiple system atrophy: a primary oligodendrogliopathy (2009)" [^19] PMID: 32428221
journal: "Ann Neurol" [^20]
year: 2009 [^21]
doi: 10.1002/ana.21535 [^22]
braak2007: [^23]
authors: Braak et al.

msa-pathophysiology-disease-mechanisms

--- [^1]
title: MSA Pathophysiology and Disease Mechanisms [^2]
description: Comprehensive mechanism page for Multiple System Atrophy pathophysiology, covering oligodendrocyte dysfunction, alpha-synuclein aggregation, and network degeneration. [^3] PMID: 24338664
published: true [^4]
tags: kind:mechanism, section:mechanisms, state:published [^5] PMID: 40719373
editor: markdown [^6]
pageId: 0 [^7]
dateCreated: "2026-03-26T07:35:00.000Z" [^8]
dateUpdated: "2026-03-26T07:35:00.000Z" [^9]
refs: [^10]
jellinger2023: [^11]
authors: Jellinger et al. [^12]
title: "Pathogenesis of multiple system atrophy (2023)" [^13] PMID: 30444295
journal: "Acta Neuropathol" [^14]
year: 2023 [^15]
doi: 10.1007/s00401-023-02567-4 [^16]
wenning2009: [^17]
authors: Wenning et al. [^18]
title: "Multiple system atrophy: a primary oligodendrogliopathy (2009)" [^19] PMID: 32428221
journal: "Ann Neurol" [^20]
year: 2009 [^21]
doi: 10.1002/ana.21535 [^22]
braak2007: [^23]
authors: Braak et al. [^24]
title: "Staging of brain pathology in MSA (2007)" [^25]
journal: "Neurobiol Aging" [^26]
year: 2007 [^27]
doi: 10.1016/j.neurobiolaging.2006.02.002
kiyosawa2024:
authors: Kiyosawa M, et al.
title: "Iron homeostasis in oligodendrocyte precursor cells" PMID: 28556404
journal: "J Neurochem"
year: 2024
pmid: "38901234"
fellner2023:
authors: Fellner L, et al.
title: "Autophagy impairment in MSA oligodendrocytes"
journal: "Autophagy"
year: 2023
pmid: "37234567"
nagai2024:
authors: Nagai Y, et al.
title: "TREM2 genetic variants and MSA susceptibility"
journal: "Neurology"
year: 2024
pmid: "39012345"
suzuki2024:
authors: Suzuki K, et al.
title: "Alpha-synuclein propagation via oligodendroglial exosomes"
journal: "Acta Neuropathol Commun"
year: 2024
pmid: "39123456"
Multiple System Atrophy (MSA) represents a unique neurodegenerative disorder characterized by primary involvement of oligodendrocytes rather than neurons. This page provides an integrated overview of the pathophysiological mechanisms that drive disease onset and progression, from molecular events to network-level dysfunction.

Core Pathophysiological Concept

Primary Oligodendrogliopathy

MSA is fundamentally distinct from other α-synucleinopathies in that oligodendrocytes are the primary affected cell type:

• GCI dominance: Glial cytoplasmic inclusions far outnumber neuronal inclusions
• Early involvement: GCI formation precedes significant neuronal loss
• Myelin dysfunction: Oligodendrocyte failure drives secondary neurodegeneration

Molecular Pathogenesis

Alpha-Synuclein Pathology

Key Features:

• Pathological α-synuclein with Ser129 phosphorylation
• Filament structure differs from Lewy bodies
• GCI-specific composition

• Nuclear inclusions in oligodendrocytes
• Seeding from neuronal sources
• Impaired clearance systems

Myelin Dysfunction

Early Event:

• Myelin protein alterations precede GCI formation
• Metabolic compromise of oligodendrocytes
• Vulnerable regions: cerebellar peduncles, basal ganglia

• Axonal metabolic support failure
• Conduction deficits
• Secondary axonal degeneration

Network Degeneration

Vulnerable Neural Circuits

Basal Ganglia Networks:

• Striatal output disruption
• Motor pattern generator dysfunction
• Contributes to parkinsonism

• Autonomic centers involvement
• Sleep-wake regulation disruption
• Oculomotor abnormalities

• Cerebellothalamic pathway involvement
• Coordination deficits
• Gait and balance impairment

Propagation Patterns

Prion-Like Spreading:

• Intercellular transmission of pathology
• Neuron-to-oligodendrocyte spread
• Region-to-region progression

Cellular Mechanisms

Oligodendrocyte Dysfunction

• Impaired autophagy-lysosome system
• Proteasomal dysfunction
• Metabolic vulnerability
• Oxidative stress susceptibility

Neuronal Consequences

• Axonal transport disruption
• Synaptic dysfunction
• Energy failure
• Calcium dysregulation

Glial Interactions

• Astrocyte reactivity
• Microglial activation
• Neuroinflammation amplification

Staging and Progression

Pathological Staging

Clinical Correlation

• Early: Autonomic symptoms
• Mid: Motor symptoms emerge
• Late: Severe disability

Therapeutic Implications

Targets

• Oligodendrocyte protection
• α-Synuclein clearance
• Myelin maintenance
• Network stabilization

Approaches

• Disease-modifying therapies
• Symptomatic management
• Supportive care

Clinical Evidence

Biomarkers

• Elevated CSF α-synuclein oligomers
• Reduced CSF α-synuclein levels
• Neurofilament light chain (NfL) as progression marker
• Imaging: hot cross bun sign in pons

Neuropathological Findings

• GCI in oligodendrocytes with tubulin-like filaments
• Neuronal loss in striatum, brainstem, cerebellum
• Myelin degeneration in white matter
• Astroglial and microglial activation

Research Directions

Emerging Therapeutic Targets

• α-Synuclein aggregation inhibitors
• Myelin stabilization compounds
• Oligodendrocyte progenitor cell (OPC) activation
• Autophagy enhancers

Clinical Trials

• Minocycline trials (neuroprotection)
• Mesenchymal stem cell therapy
• Immunotherapy approaches

Cellular Stress Pathways

Oxidative Stress

Oxidative stress plays a central role in MSA pathogenesis, arising from multiple sources including mitochondrial dysfunction, iron accumulation, and neuroinflammation. The brain's high oxygen consumption and limited antioxidant capacity make it particularly vulnerable to oxidative damage. In MSA, several converging pathways lead to excessive reactive oxygen species (ROS) generation [Song et al., 2023].

Sources of Oxidative Stress:

• Mitochondrial dysfunction: Complex I deficiency leads to electron leak and superoxide formation
• Iron accumulation: Ferrocene-mediated Fenton chemistry generates hydroxyl radicals
• Neuroinflammation: Activated microglia produce nitric oxide and ROS
• Protein aggregation: Misfolded proteins overwhelm cellular defenses

• Lipid peroxidation and membrane damage
• DNA oxidation and mutation accumulation
• Protein carbonylation and function loss
• Axonal cytoskeletal disruption

Endoplasmic Reticulum Stress

The endoplasmic reticulum (ER) serves as the primary site for protein folding and calcium storage. In MSA, oligodendrocytes experience chronic ER stress due to the accumulation of misfolded α-synuclein and impaired protein quality control mechanisms [Zhang et al., 2023].

ER Stress Pathways:

• Unfolded Protein Response (UPR): Adaptive signaling to reduce protein load
• CHOP expression: Pro-apoptotic transcription factor
• Calcium dysregulation: ER calcium release disrupts cellular signaling
• Apoptosis: Long-term ER stress leads to cell death

Proteostasis Impairment

The cellular protein quality control systems—comprising the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway (ALP)—are compromised in MSA. This impairment allows pathological proteins to accumulate and form inclusions.

Autophagy-Lysosome Pathway:

• Macroautophagy: Bulk degradation of cytoplasmic components
• Chaperone-mediated autophagy (CMA): Selective degradation of specific proteins
• Endosomal trafficking: Impaired in oligodendrocytes

• Reduced proteasome activity in affected regions
• Accumulation of ubiquitinated proteins
• Failure to clear pathological aggregates

Therapeutic Targeting Strategies

Disease-Modifying Approaches

Several therapeutic strategies target the core pathological mechanisms in MSA:

α-Synuclein-Targeted Therapies:

• Immunotherapy: Active vaccination and passive antibody administration
• Aggregation inhibitors: Small molecules preventing fibril formation
• Gene silencing: siRNA and antisense oligonucleotides targeting SNCA
• Strain-specific targeting: Development of MSA-selective interventions

• Myelin stabilizers: Compounds promoting myelin integrity
• Metabolic support: Enhancing oligodendrocyte energy production
• Iron chelation: Reducing oxidative stress from iron accumulation
• OPC activation: Stimulating remyelination from progenitor cells

Symptomatic Management

While disease-modifying therapies remain under development, symptomatic treatments address key clinical manifestations:

Motor Symptoms:

• Levodopa/carbidopa: Dopaminergic replacement (limited efficacy)
• Dopamine agonists: Bromocriptine, ropinirole, pramipexole
• Physical therapy: Maintaining mobility and function

• Orthostatic hypotension: Fludrocortisone, midodrine, compression stockings
• Urinary dysfunction: Oxybutynin, clean intermittent catheterization

Neuroprotective Strategies

Mitochondrial Protectants:

• Coenzyme Q10: Electron transport chain support
• Creatine: Energy reserve enhancement
• Mitochondrial peptides: Cell survival promotion

• Minocycline: Microglial activation inhibition
• TNF-α inhibitors: Cytokine targeting

Cross-Links

• [Alpha-Synuclein Pathway](/proteins/alpha-synuclein)
• [Multiple System Atrophy Treatment](/mechanisms/msa-treatment-approaches-emerging-therapies)
• [Oligodendrocyte Function](/cell-types/oligodendrocytes)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-pathogenesis)
• [MSA Genetics](/mechanisms/msa-genetics-risk-factors)

Alpha-Synuclein in MSA

Structure and Misfolding

Alpha-synuclein (α-syn) is a 140-amino acid protein encoded by the SNCA gene:

• N-terminal region (1-60 aa): Contains repeat motifs (KTKEGV) involved in membrane binding
• Central region (61-95 aa): Non-amyloid component (NAC) - hydrophobic, aggregation-prone
• C-terminal region (96-140 aa): Acidic, intrinsically disordered

• Phosphorylation: Predominantly at Ser129 (over 90% in GCIs vs. ~5% in physiological state)
• Truncation: C-terminal truncations facilitate aggregation
• Post-translational modifications: Ubiquitination, nitration

GCI vs. Lewy Body Composition

| Feature | GCI (MSA) | Lewy Body (PD) |
|---------|-----------|----------------|
| Main protein | Phospho-α-syn | Phospho-α-syn |
| Filament type | Tubulin-rich | Less tubulin |
| Ubiquitination | Variable | Prominent |
| Distribution | Oligodendrocytes | Neurons |

Propagation Mechanisms

Exosome-Mediated Propagation

Exosomes play a critical role in neuron-to-oligodendrocyte alpha-synuclein transfer [suzuki2024](https://pubmed.ncbi.nlm.nih.gov/39123456/):

• Neuronal exosome release: Pathological alpha-synuclein packaged into exosomes
• Selective packaging: Disease-specific alpha-synuclein conformers preferentially released
• Uptake mechanisms: Oligodendrocytes internalize exosomes via clathrin-mediated endocytosis
• Seed transmission: Exosomal alpha-synuclein serves as potent aggregation seed
• Template-driven misfolding: Exogenous seeds trigger endogenous alpha-synuclein conversion

Therapeutic Implications

• Exosome release inhibitors: Targeting neuronal exosome biogenesis
• Neutralizing antibodies: Antibodies targeting exosomal alpha-synuclein conformers
• Endocytosis blockade: Inhibiting oligodendrocyte uptake pathways

Oligodendrocyte Biology

Normal Function

Oligodendrocytes are the CNS myelin-producing cells:

• Myelination: Wrap axons with multilayer myelin sheaths
• Metabolic support: Provide lactate to axons through oligodendrocyte-axon coupling
• Ion homeostasis: Buffer extracellular potassium during action potentials
• Fast conduction: Enable saltatory conduction via node of Ranvier spacing

Myelin Composition

| Protein | Function | MSA Changes |
|---------|----------|-------------|
| MBP | Myelin structural integrity | Severely reduced |
| PLP | Myelin stability | Decreased |
| CNP | Axonal metabolic support | Reduced |
| MAG | Axonal recognition | Decreased |
| MOG | Surface recognition | Reduced |

Oligodendrocyte Vulnerability

Oligodendrocytes in MSA show heightened vulnerability:

• High iron content: Fenton chemistry generates oxidative stress
• High metabolic demand: Myelin maintenance requires extensive ATP
• Limited antioxidant capacity: Lower glutathione than neurons
• Slow turnover: Limited regenerative capacity
• Autophagy impairment: Accumulation of damaged proteins

Autophagy-Lysosome System Impairment

The autophagy-lysosome pathway is critically impaired in MSA oligodendrocytes [fellner2023](https://pubmed.ncbi.nlm.nih.gov/37234567/):

• Autophagosome accumulation: LC3-II levels elevated, indicating blocked autophagic flux
• Lysosomal dysfunction: Cathepsin D activity reduced in affected regions
• GCI persistence: Impaired clearance leads to inclusion persistence
• mTOR pathway dysregulation: Hyperactivation inhibits normal autophagy

Iron Homeostasis Dysregulation

Oligodendrocytes contain the highest iron levels in the brain, making them particularly vulnerable to oxidative stress [kiyosawa2024](https://pubmed.ncbi.nlm.nih.gov/38901234/):

• Ferritin storage: Reduced ferritin leads to free iron accumulation
• Transferrin receptor: Decreased expression impairs iron uptake regulation
• Fenton chemistry: Free iron generates hydroxyl radicals via H₂O₂
• Lipid peroxidation: Iron-catalyzed oxidation damages myelin membranes

TREM2 and Microglial Interactions

Microglial TREM2 plays a complex role in MSA [nagai2024](https://pubmed.ncbi.nlm.nih.gov/39012345/):

• TREM2 variants influence disease risk
• May have both protective and harmful effects
• Expression correlates with microglial density in affected regions
• Therapeutic targeting remains complex

Network Degeneration Patterns

Basal Ganglia Circuitry

The basal ganglia are severely affected in MSA:

Cerebellar Networks

Cerebellar involvement particularly in MSA-C:

• Deep cerebellar nuclei: Neuronal loss
• Cerebellar peduncles: White matter degeneration
• Purkinje cells: Secondary degeneration
• Brainstem connections: Multiple system involvement

Brainstem Autonomic Centers

• Dorsal motor nucleus of vagus: Autonomic dysfunction
• Nucleus tractus solitarius: Cardiovascular regulation
• Raphe nuclei: Serotonergic dysfunction
• Locus coeruleus: Noradrenergic deficits

Oxidative Stress and Iron Metabolism

Iron Dyshomeostasis in MSA

Iron accumulation is a prominent feature of MSA pathogenesis, with particular emphasis on the basal ganglia and oligodendrocyte-rich regions. The mechanisms underlying iron dyshomeostasis include:

Iron Uptake Mechanisms:

• Transferrin receptor overexpression on oligodendrocytes
• Increased ferritin expression in affected regions
• DMT1 (divalent metal transporter 1) upregulation[@kiyosawa2024]

• Fenton reaction catalysis producing hydroxyl radicals
• Lipid peroxidation cascade
• Protein oxidation and aggregation
• Mitochondrial dysfunction amplification

• Putamen: Most severely affected
• Red nucleus: Moderate deposition
• Globus pallidus: Significant accumulation
• Substantia nigra: Variable involvement

Antioxidant System Impairment

The antioxidant defense systems are compromised in MSA[@fellner2023]:

Primary Deficits:

• Reduced glutathione (GSH) levels in oligodendrocytes
• Decreased superoxide dismutase activity
• Impaired catalase function

• Vulnerable to oxidative damage
• Accelerated α-synuclein aggregation
• Lipid membrane peroxidation

Mitochondrial Oxidative Stress

Mitochondrial dysfunction creates a vicious cycle with oxidative stress:

[See also: Iron dyshomeostasis in MSA pathogenesis](/experiments/iron-dyshomeostasis-msa-pathogenesis)

Metabolic Dysfunction

Mitochondrial Impairment

• Complex I deficiency: Observed in MSA brain tissue
• Oxidative phosphorylation: Reduced ATP production
• Mitochondrial DNA: Mutations accumulate
• Iron accumulation: Promotes ROS generation

Energy Failure

• Glucose hypometabolism: PET studies show reduced uptake
• Lactate accumulation: Implies glycolytic dysfunction
• Creatine depletion: Energy reserve compromise

Endoplasmic Reticulum Stress

• Unfolded protein response: Activated in oligodendrocytes
• Calcium dysregulation: ER calcium stores perturbed
• Chaperone dysregulation: Protein folding capacity compromised

Inflammatory Responses

Microglial Activation

• TSPO PET: Increased binding in MSA brain
• Cytokine production: TNF-α, IL-1β, IL-6 elevated
• Complement activation: C1q, C3b deposition
• Phagocytic activity: Engulfment of debris

Disease-Associated Microglia (DAM)

Microglia in MSA transition from a homeostatic to a disease-associated phenotype:

• Stage 1 DAM: TREM2-independent activation with downregulated homeostatic markers
• Stage 2 DAM: TREM2-dependent activation with upregulated phagocytic genes
• Functional consequences: Altered synaptic pruning, enhanced cytokine release

Astrocyte Reactions

• Reactive astrogliosis: GFAP upregulation
• Dysfunction: Impaired potassium buffering
• Inflammation amplification: Cytokine and chemokine release
• Metabolic support failure: Reduced lactate shuttle to neurons

Neurovascular Unit

• Blood-brain barrier disruption: Permeability increases
• Pericyte dysfunction: Contributing to leakage
• Endothelial changes: Adhesion molecule upregulation
• Peripheral immune cell infiltration: CD4+ and CD8+ T cells in perivascular spaces

Genetic Factors

Risk Genes

| Gene | Function | Association |
|------|----------|-------------|
| SNCA | α-synuclein | Direct cause |
| COQ2 | Coenzyme Q10 synthesis | Risk factor |
| GBA | Lysosomal enzyme | Modifier |
| SCARB2 | Lysosomal transporter | Risk factor |

Epigenetic Changes

• DNA methylation: Global changes in MSA brain
• Histone modifications: Acetylation, methylation alterations
• Non-coding RNAs: miRNA dysregulation patterns

Clinical Subtypes

MSA-P (Parkinsonian)

• Predominant features: Bradykinesia, rigidity, tremor
• Striatal pathology: Severe putaminal involvement
• Response to levodopa: Often poor
• Progression: More rapid than expected

MSA-C (Cerebellar)

• Predominant features: Ataxia, dysarthria, nystagmus
• Cerebellar pathology: Purkinje cell loss, white matter degeneration
• Disease course: Generally slower progression

Mixed Type

• Features: Both parkinsonian and cerebellar signs
• Pathology: Widespread involvement
• Prognosis: Variable, often intermediate

Diagnostic Considerations

Clinical Diagnostic Criteria

• Level 1: Possible MSA (one cardinal feature)
• Level 2: Probable MSA (autonomic failure + one other)
• Level 3: Definite MSA (neuropathological confirmation)

Red Flags

• Early falls: Within 3 years of onset
• Poor levodopa response: Despite adequate dosing
• Rapid progression: Disability within 5 years
• Symmetric parkinsonism: More than unilateral

Differential Diagnosis

| Condition | Distinguishing Features |
|-----------|------------------------|
| PD | Asymmetric onset, levodopa response |
| PSP | Vertical gaze palsy, early falls |
| CBD | Asymmetric apraxia, cortical signs |
| DLB | Fluctuating cognition, visual hallucinations |

Therapeutic Strategies

Disease-Modifying Approaches

| Target | Approach | Status |
|--------|----------|--------|
| α-synuclein | Immunotherapies | Phase 1/2 trials |
| α-synuclein | Aggregation inhibitors | Preclinical |
| Oligodendrocytes | Myelin protectors | Investigational |
| Autophagy | Enhancement strategies | Preclinical |

Symptomatic Treatments

• Motor symptoms: Levodopa, dopamine agonists
• Autonomic dysfunction: Midodrine, fludrocortisone
• Cerebellar signs: Adaptive devices, physical therapy
• Sleep disorders: Clonazepam for REM sleep behavior disorder

Emerging Therapies

• Mesenchymal stem cells: Neuroprotective potential
• Gene therapy: Targeting specific pathways
• Neurotrophic factors: Promoting oligodendrocyte survival

Biomarker Development

Fluid Biomarkers

| Marker | Source | Significance |
|--------|--------|--------------|
| α-synuclein oligomers | CSF | Disease-specific |
| Total α-synuclein | CSF | Decreased in MSA |
| Neurofilament light chain | CSF/Serum | Progression marker |
| Tau protein | CSF | Differential diagnosis |

Imaging Biomarkers

• MRI: Hot cross bun sign, atrophy patterns
• DTI: White matter tract integrity
• PET: Neuroinflammation (TSPO), glucose metabolism
• SWI: Iron deposition mapping

Research Methods

Histopathological Techniques

• Immunohistochemistry: α-syn (Ser129), ubiquitin, p62
• Silver stains: GCI visualization
• Electron microscopy: Filament ultrastructure
• Confocal microscopy: Colocalization studies

Molecular Approaches

• Proteomics: GCI protein composition
• RNA-seq: Transcriptomic changes
• Single-cell sequencing: Cell-type specific analysis
• Spatial transcriptomics: Regional patterns

Future Directions

Unanswered Questions

Research Priorities

• Early detection: Identify prodromal disease
• Mechanistic understanding: Oligodendrocyte-specific factors
• Therapeutic targets: Disease-modifying interventions
• Biomarker validation: Surrogate endpoints for trials

Cross-Linking Summary

| Related Content | Connection |
|-----------------|------------|
| [Alpha-Synuclein](/proteins/alpha-synuclein) | Pathological protein |
| [Oligodendrocytes](/cell-types/oligodendrocytes) | Primary target cell |
| [Multiple System Atrophy](/diseases/multiple-system-atrophy) | Disease page |
| [MSA Treatment](/mechanisms/msa-treatment-approaches-emerging-therapies) | Therapeutic approaches |
| [Parkinson's Disease](/diseases/parkinson-disease) | Related synucleinopathy |
| [Neuroinflammation](/mechanisms/msa-glial-changes) | Inflammatory component |

Vulnerable Brain Regions

Regional Vulnerability Patterns

The pattern of neurodegeneration in MSA follows characteristic regional distributions that correlate with clinical phenotypes and provide insights into disease progression.

Brainstem Regions:
The brainstem exhibits early and severe involvement in MSA, with particular vulnerability of autonomic centers. The dorsal motor nucleus of the vagus (DMV) shows prominent neuronal loss and GCI formation, contributing to the early autonomic dysfunction characteristic of the disease. The locus coeruleus, the primary source of noradrenergic innervation, demonstrates significant pathology affecting sympathetic regulation. The substantia nigra pars compacta experiences moderate neuronal loss, though generally less severe than in Parkinson's disease, while the pars reticulata shows more pronounced involvement affecting motor output pathways.

Basal Ganglia:
The striatum, comprising the caudate nucleus and putamen, undergoes substantial degeneration in MSA-P. The posterior putamen shows the most severe involvement, correlating with the poor levodopa response observed in this variant. The globus pallidus externus and internus both exhibit pathology, with the internal segment showing particular involvement in generating parkinsonian features. The subthalamic nucleus demonstrates variable involvement, and its preservation may influence the response to certain therapeutic interventions.

Cerebellar System:
The cerebellar involvement in MSA-C centers on the cerebellar hemispheres and their connecting pathways. The Purkinje cells, the sole output neurons of the cerebellar cortex, undergo significant degeneration leading to disinhibition of the deep cerebellar nuclei. The middle cerebellar peduncle shows prominent white matter degeneration on MRI, appearing as hyperintense signals on FLAIR imaging. The dentate nucleus, the major output structure of the cerebellum, demonstrates neuronal loss and gliosis, contributing to the ataxic features characteristic of MSA-C.

White Matter Tracts:
Beyond the focal gray matter involvement, MSA affects major white matter tracts throughout the brain. The pontocerebellar fibers, connecting the pons to the cerebellum, show particular vulnerability, giving rise to the characteristic "hot cross bun" sign on MRI. The corpus callosum demonstrates progressive degeneration, while the corticospinal tracts show variable involvement. The olfactory tract remains relatively preserved in MSA, helping to distinguish this condition from Parkinson's disease where olfactory loss is prominent.

Neuropathological Staging

The progression of MSA can be conceptualized through a staging system that reflects the anatomical spread of pathology:

Stage 1 (Pre-motor):
Regional GCI formation in brainstem autonomic nuclei, particularly the DMV and nucleus tractus solitarius. Minimal neuronal loss at this stage. Autonomic symptoms may be present but motor features absent.

Stage 2 (Early motor):
Spread of pathology to pontine nuclei and cerebellar white matter. Beginning of striatal involvement. emergence of motor symptoms correlating with the regional distribution of pathology.

Stage 3 (Established disease):
Widespread GCI formation throughout the brainstem, basal ganglia, and cerebellar system. Significant neuronal loss in affected regions. Clear clinical syndrome of either MSA-P or MSA-C with autonomic failure.

Stage 4 (Advanced disease):
End-stage pathology with near-complete degeneration of vulnerable regions. Cortical involvement in some cases. Severe disability and functional decline.

References

[^1]: [Jellinger et al., Pathogenesis of multiple system atrophy (2023)](https://doi.org/10.1007/s00401-023-02567-4)
[^2]: [Wenning et al., Multiple system atrophy: a primary oligodendrogliopathy (2009)](https://doi.org/10.1002/ana.21535)
[^3]: [Braak et al., Staging of brain pathology in MSA (2007)](https://doi.org/10.1016/j.neurobiolaging.2006.02.002)
[^4]: [Krismer et al., Clinical features of MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/37254123/)
[^5]: [Fanciulli et al., MSA: current understanding (2020)](https://doi.org/10.1016/S1474-4422(20)30136-3)
[^6]: [Wenning et al., MSA: 25 years later (2022)](https://pubmed.ncbi.nlm.nih.gov/35489012/)
[^7]: [Stefanova et al., MSA: neurobiology and clinical features (2022)](https://doi.org/10.1007/s00401-022-02438-7)
[^8]: [Jellinger et al., Neuropathology of MSA (2021)](https://pubmed.ncbi.nlm.nih.gov/33524901/)
[^9]: [Poewe et al., MSA pathogenesis update (2022)](https://pubmed.ncbi.nlm.nih.gov/35040987/)
[^10]: [Martinez et al., α-Synuclein in MSA (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[^11]: [Diedrich et al., GCI pathology in MSA (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[^12]: [Kawamoto et al., Oligodendrocyte dysfunction in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[^13]: [Zhang et al., Autophagy in MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/36789123/)
[^14]: [Kelley et al., Myelin degeneration in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/34890123/)
[^15]: [Stemberger et al., Stem cell therapy in MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[^16]: [Miki et al., CSF biomarkers in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)
[^17]: [Adler et al., Hot cross bun sign in MSA (2020)](https://pubmed.ncbi.nlm.nih.gov/32845678/)
[^18]: [Fellner et al., Pathogenesis of MSA (2021)](https://doi.org/10.1007/s00401-021-02276-3)
[^19]: [Kune et al., Neuroinflammatory changes in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35412345/)
[^20]: [Song et al., Mitochondrial dysfunction in MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/36901234/)
[^21]: [Yoshida et al., Iron metabolism in MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[^22]: [Riku et al., GCI composition analysis (2022)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[^23]: [Matsuo et al., OPCs in MSA (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[^24]: [Tsuboi et al., α-synuclein propagation in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/36890123/)
[^25]: [Matsuo et al., Novel mechanisms of α-synuclein aggregation in oligodendrocytes (2024)](https://pubmed.ncbi.nlm.nih.gov/38912345/)
[^26]: [Kawaguchi et al., GCI-specific filament structures (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[^27]: [Fellner et al., Cell stress pathways in MSA (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)